International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 531-536 , June 2010

In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial species

  • David J. Farrell

      Affiliations

    • Quotient Bioresearch Ltd., Newmarket Road, Fordham, Cambridgeshire CB7 5WW, UK
    • Present address: JMI Laboratories, 345 Beaver Kreek Centre, North Liberty, IA 52317, USA.
    • ,
  • Marion Robbins

      Affiliations

    • Quotient Bioresearch Ltd., Newmarket Road, Fordham, Cambridgeshire CB7 5WW, UK
    • ,
  • William Rhys-Williams

      Affiliations

    • Destiny Pharma Ltd., Sussex Innovation Centre, Science Park Square, Falmer, Brighton BN1 9SB, UK
    • ,
  • William G. Love

      Affiliations

    • Destiny Pharma Ltd., Sussex Innovation Centre, Science Park Square, Falmer, Brighton BN1 9SB, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 1273 704 440; fax: +44 1273 704 414.

Received 6 November 2009 ,Accepted 10 February 2010.

References 

  1. Health Protection Agency. Surveillance of healthcare associated infections report 2007. London, UK: HPA; 2007. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1196942169446 [accessed 16 February 2010].
  2. US Centers for Disease Control and Prevention. MRSA in healthcare settings. Atlanta, GA: CDC; 2007. http://www.cdc.gov/ncidod/dhqp/ar_MRSA_spotlight_2006.html [accessed 16 February 2010].
  3. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666–674
  4. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med. 2006;144:309–317
  5. Al-Rawahi GN, Reynolds S, Porter SD, Forrester L, Kishi L, Chong T, et al. Community-associated CMRSA-10 (USA-300) is the predominant strain among methicillin-resistant Staphylococcus aureus strains causing skin and soft tissue infections in patients presenting to the emergency department of a Canadian tertiary care hospital. J Emerg Med. 2010;38:6–11
  6. Kourbatova EV, Halvosa JS, King MD, Ray SM, White N, Blumberg HM. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health care-associated infections among patients with prosthetic joint infections. Am J Infect Control. 2005;33:385–391
  7. Gonzalez BE, Rueda AM, Shelburne SA, Musher DM, Hamill RJ, Hulten KG. Community-associated strains of methicillin-resistant Staphylococcus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol. 2006;27:1051–1056
  8. Seybold U, Kourbatova EV, Johnson JG, Halvosa SJ, Wang YF, King MD, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis. 2006;42:647–656
  9. Rhys-Williams W, Love W, Hayter I, Farrell DJ, Janes R, Robbins M. XF-73: a novel antimicrobial—investigation of the change in MIC against multiple MRSA strains during a 55-passage study. Eur J Clin Microbiol Infect. 2008;14(Suppl. 7):S130
  10. Ooi N, Miller K, Hobbs J, Rhys-Williams W, Love W, Chopra I. XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity. J Antimicrob Chemother. 2009;64:735–740
  11. Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA). http://www.narsa.net/content/home.jsp [accessed 16 February 2010].
  12. Love WG, Rhys-Williams W, Hayter I, Farrell DJ, Janes R, Robbins M. XF-73: a new antimicrobial drug—comparison with daptomycin for the development of mutational resistance in MRSA USA300 in a 55-passage study. In: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th Annual Meeting, 25–28 October 2008, Washington, DC. ASM Press; 2008;[Abstract F1-3970]
  13. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard. 7th ed. Document M11-A7. Wayne, PA: CLSI; 2007.
  14. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M7-A7. Wayne, PA: CLSI; 2007.
  15. Clinical and Laboratory Standards Institute. Methodology for the serum bactericidal test; approved guideline M21-A. Page 15, Table 1. ‘Rejection value and calculated sensitivity and specificity for each initial concentration on the basis of duplicate 0.01ml samples’. Wayne, PA: CLSI; 1999.
  16. Craig WA, Gudmundsson S. The postantibiotic effect. In:  Lorian V editors. Antibiotics in laboratory medicine. 3rd ed.. Baltimore, MD: Williams & Wilkins Co.; 1991;p. 403–431
  17. Vogelman BS, Craig WA. Postantibiotic effects. J Antimicrob Chemother. 1985;15(Suppl. A):37–46
  18. Zhanel GC, Hoban DJ, Harding GKM. The postantibiotic effect: a review of in vitro and in vivo data. DICP. 1991;25:153–163
  19. Stephens J, Davies L. The war on superbugs. Scrip Magazine. 2008;2401/02:44–47
  20. Livermore DM. Antibiotic uptake and transport by bacteria. Scand J Infect Dis Suppl. 1990;74:15–22
  21. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:2538–2544
  22. Ooi N, Miller K, Randall C, Rhys-Williams W, Love W, Chopra I. XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms. J Antimicrob Chemother. 2010;65:72–78

PII: S0924-8579(10)00082-8

doi: 10.1016/j.ijantimicag.2010.02.008

International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 531-536 , June 2010

Article Tools

* Image Usage & Resolution